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Abstract: Vandetanib (ZD6474) is an oral small molecule inhibitor of multiple intracellular 
receptor kinases, including the vascular endothelial growth factor receptor (VEGFR) -2 and 
epidermal growth factor receptor (EGFR). Both VEGFR and EGFR pathways have emerged 
as instrumental in the growth and metastasis of multiple malignancies, including non-small 
cell lung cancer (NSCLC). Indeed, inhibitors of each pathway have been approved by the US 
Food and Drug Administration for use in advanced NSCLC. As there is considerable cross talk 
between these pathways, dual inhibition with such agents has become an attractive strategy, 
with encouraging Phase II clinical trial data to date. The convenience of one oral agent targeting 
both pathways is clear, and clinical trials have established the maximum tolerated daily dose 
of vandetanib, with data from randomized Phase III trials emerging. This report will review 
completed and ongoing NSCLC clinical trials evaluating vandetanib, and speculate on the 
future of this agent in NSCLC.
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Introduction
Lung cancer continues to be the leading cause of cancer related mortality worldwide, 
accounting for over one million deaths annually.1 The majority of patients present with 
metastatic disease, with a median survival of six months.2 Approximately 85% of lung 
cancers are classified as non-small cell lung cancer (NSCLC), which can be further 
subdivided in adenocarcinoma, squamous cell carcinoma and large cell   carcinoma 
histology. Chemotherapy remains the cornerstone of treatment in advanced NSCLC; 
however, a plateau of effectiveness with such therapy has been reached. Molecularly 
targeted agents have further improved outcome over the last decade, and several addi-
tional targeted agents are being developed.
To date, three targeted agents have been approved by the US Food and Drug 
  Administration (FDA) in advanced NSCLC. The first to receive FDA approval was 
gefitinib, a small molecule inhibitor of the epidermal growth factor receptor (EGFR) 
tyrosine kinase, a transmembrane receptor whose activation leads to intracellular 
  signaling involved in cancer cell proliferation and survival. Gefitinib was later restricted 
to use only in those who were previously benefiting, as a Phase III trial comparing gefi-
tinib to best supportive care did not ultimately find a survival advantage.3 The second 
drug to be granted approval was erlotinib, another small molecule inhibitor of the EGFR 
tyrosine kinase, which is currently indicated as second or third line therapy in patients 
with advanced NSCLC. The last FDA-approved agent is bevacizumab, a humanized Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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monoclonal antibody to the vascular endothelial growth 
factor (VEGF), a key mediator of angiogenesis required for 
growth and metastasis of cancer. A trial conducted by the 
Eastern Cooperative Oncology Group (ECOG) found that the 
addition of bevacizumab to first line chemotherapy with car-
boplatin and paclitaxel led to improved response and survival, 
with a landmark median survival of one year.4 Cetuximab is 
another promising monoclonal antibody which targets the 
extracellular ligand binding domain of EGFR, and a recent 
Phase III study found a modest improvement in survival when 
this agent was combined with cisplatin and vinorelbine in 
patients with chemonaive advanced NSCLC.5 The US FDA 
is currently considering approval of this drug.
Clearly, the EGFR and VEGF pathways have been 
  clinically validated as important targets in the treatment of 
NSCLC. Preclinical studies further   suggest that combined 
inhibition of both pathways may lead to synergistic effects on 
cancer cell growth, survival and metastases.6–8 The rationale for 
dual inhibition comes from our increased understanding of the 
redundancy of these pathways and their interconnectedness.
vascular endothelial growth factor 
receptor (VEGFR) Pathway
Three transmembrane receptors mediate the angiogenic and lym-
phogenic effects of VEGF; VEGFR-1 (Flt-1), -2 (KDR), and -3 
(Flt-4).9 Of these, VEGFR-2 is believed to play the primary role 
in endothelial cell proliferation, migration, survival and induction 
of vascular permeability   characteristic of neo-vascularization 
required for tumor growth and metastasis.10,11 VEGFR-2 is 
activated by binding of VEGF elaborated by tumor cells, which 
leads to receptor dimerization and intracellular signaling initiated 
by the VEGFR tyrosine kinase.11,12 This ultimately results in the 
production of tumor vasculature that is highly permeable, dilated 
and tortuous, with increased tumor interstitial pressure that may 
impede delivery of cytotoxic agents.13 The resultant increasingly 
hypoxic microenvironment in turn upregulates expression of 
VEGF contributing to further neo-vascularization.
eGFR Pathway
Like the VEGFR, the EGFR is activated by ligand (ie, 
EGF, TGF-α) binding leading to receptor dimerization and 
  autophosphorylation of its intracellular tyrosine kinase 
domain. This kinase in turn phosphorylates other proteins, 
initiating a cascade of signaling events responsible for cell pro-
liferation, cell survival, metastasis and angiogenesis.14 EGFR 
is overexpressed in several solid tumors, including   NSCLC.15 
Activating mutations in the EGFR gene have   additionally been 
identified that lead to constitutive activity of the intracellular 
tyrosine kinase and predict for high response rates to the 
small molecule EGFR inhibitors, erlotinib and gefitinib.16–19 
Although only   approximately 10%–15% of NSCLCs harbor 
EGFR   mutations, it is   estimated that up to 50% of lifelong 
nonsmokers with NSCLC have EGFR mutant tumors.20 The 
reliance of these mutant tumors on the EGFR pathway has 
led to the term oncogene addiction.
Crosstalk between veGFR and eGFR 
Pathways
Both in vitro and in vivo data have established that activation 
of EGFR by its ligands can lead to increased VEGFR expres-
sion and neovascularization in cancer models.21,22 Indeed, 
both small molecule inhibitors and antibodies to EGFR (and 
downstream signaling mediators) have resulted in decreased 
VEGF expression and cell death in cancer cell lines and 
animal models.23–25 VEGF over expression may also mediate 
resistance to EGFR antagonists, with preclinical data support-
ing efforts to overcome acquired resistance with the addition 
of a VEGF inhibitor, and delaying emergence of resistance 
with upfront dual inhibition.26 Combining   bevacizumab and 
erlotinib in the clinic is a particularly appealing strategy, 
considering good tolerance of each agent alone, with lack of 
overlapping toxicities. This regimen has been well tolerated in 
a Phase II NSCLC clinical trial that showed promising activity, 
and the final results of two Phase III trials are awaited.27–29
vandetanib (ZD6474, ZactimaTM;  
AstraZeneca) (N-(4-bromo-2-  
fluorophenyl)-6-methoxy-7-  
[(1-methylpiperidin-4-yl)methoxy]
quinazolin-4-amine)
Vandetanib is an oral anilinquinazoline that competes with 
ATP binding in the catalytic domain of several tyrosine 
kinases.30 Recombinant enzyme assays haves shown it to be 
a potent inhibitor of VEGFR-2 (50% inhibitory   concentration 
[IC50] of 40 nM), with additional activity against VEGFR-3 
(IC50 110 nM), EGFR (IC50 500 nM) and the rearranged 
  during transfection (RET; IC50130 nM) kinase. Further   studies 
on human umbilical vein endothelial cells (HUVEC) have 
found vandetanib to potently inhibit proliferation of VEGFR 
stimulated cells (IC50 60 nM) with higher doses   necessary for 
EGFR stimulated HUVEC proliferation (IC50 170 nM). Addi-
tional in vitro and in vivo studies have also demonstrated that 
vandetanib inhibits cell growth of several human cancer cell Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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lines that have functional EGFR but are devoid of VEGFR-2, 
and further potentiates the anti-  proliferative effects of doc-
etaxel and paclitaxel.21,31 Xenograft models have in turn shown 
dose dependent inhibition of tumor growth with vandetanib, 
including NSCLC tumors resistant to gefitinib, and reduction 
in tumor microvessel density and inhibition of new blood 
vessel formation.30,32–34 Together, these and other preclinical 
studies suggest the effect of vandetanib on tumor growth and 
survival is mediated by both the EGFR and VEGR pathways, 
and support further clinical evaluation.
Phase I studies
Two Phase I dose escalation studies evaluating daily   vandetanib 
alone in advanced solid tumors have been   completed. The first 
was conducted in the United States and Australia, enrolling 
77 patients, with colon cancer being the most common tumor 
type.35 Dose limiting toxicities included diarrhea, hypertension 
and rash. The recommended dose to evaluate in further studies 
was 300 mg daily. This dose was tolerated well, with the most 
common toxicities being rash and diarrhea. Asymptomatic QTc 
prolongation was also observed in 7 patients. Pharmacokinetic 
studies showed vandetanib to be extensively distributed, with a 
half life of approximately 120 hours and a minimum of 28 days 
continuous oral dosing required to achieve steady-state plasma 
concentrations. The second Phase I study was conducted in 
Japan, and enrolled 18 patients.36 Again, 300 mg daily was 
determined to be the recommended dose with similar toxicity 
profile and pharmacokinetic findings. Of note, four of nine 
patients with advanced refractory NSCLC achieved a partial 
response per Response Evaluation Criteria in Solid Tumors 
(RECIST) criteria at doses of 200 or 300 mg daily.
A third Phase I trial further evaluated vandetanib in 
  combination with pemetrexed, a newer anti-folate approved 
for use in advanced nonsquamous NSCLC.37 Only patients 
with advanced NSCLC who failed first line chemotherapy 
were eligible. Two dose levels of vandetanib were   evaluated, 
100 mg and 300 mg daily, given with full doses of   pemetrexed 
every three weeks. Both doses were well tolerated, without 
obvious pharmacokinetic interactions. Of the 21 patients 
enrolled, one achieved a partial response by RECIST   criteria 
(from the vandetanib 100 mg cohort), and an additional 
13 patients had stabilization of disease.
Phase II studies
Based on encouraging activity in Phase I studies with good 
tolerability of vandetanib up to 300 mg daily, four   randomized 
Phase II trials evaluating vandetanib alone and in   combination 
with chemotherapy have been conducted in advanced NSCLC 
(Table 1).38–41 These trials confirmed the good tolerability 
of vandetanib seen in Phase I studies, with modest activity 
supporting Phase III evaluations. The most common side 
effects experienced were rash, diarrhea, hypertension, and 
asymptomatic prolonged QTc interval. In the two studies 
where vandetanib was combined with chemotherapy, there 
were no pharmacokinetic   interactions. Interestingly, the study 
evaluating two dose levels of   vandetanib with standard doc-
etaxel dosing suggested that a lower dose of vandetanib may 
be more beneficial when combined with chemotherapy. One 
hypothesis offered to explain this has been that with greater 
inhibition of EGFR achieved with higher doses of vandetanib, 
cancer cell proliferation is decreased with G1 cell cycle arrest 
compromising effectiveness of cell cycle   phase-dependent 
activity of chemotherapy.42 Four Phase III trials evaluating 
the addition of a small molecule EGFR inhibitor (erlotinib 
or gefitinib) to standard first line chemotherapy support this, 
with no benefit appreciated.43–46
Correlative studies from the randomized Phase II studies 
included serum markers (ie, several cytokines and angiogenic 
factors including VEGF) and tumor tissue analysis for EGFR 
and KRAS mutational status, and EGFR gene copy number by 
FISH.38,41,47,48 Limited samples preclude any conclusions; how-
ever, there was a suggestion that circulating VEGF   levels may 
be a potential biomarker, with lower values being more predic-
tive of benefit. Additional biomarker studies are clearly needed, 
and such analyses from Phase III studies are awaited.
Phase III studies
Three Phase III clinical trials evaluating vandetanib were 
presented at the American Society of Clinical Oncology 
(ASCO) annual meeting in 2009 and are awaiting formal 
publication. Two of the studies investigated vandetanib in 
combination with standard second-line chemotherapy, and 
the third compared vandetanib to erlotinib.
ZeST
Based on the Phase II study by Natale et al39 showing   promising 
data for vandetanib versus gefitinib as monotherapy in previously 
treated NSCLC (Table 1), the ZEST (ZACTIMA Efficacy Study 
versus Tarceva) trial was designed with the primary objective to 
show superiority in progression-free survival (PFS) for vande-
tanib versus erlotinib.49 A total of 1,240 patients with advanced 
lung cancer who had received previous therapy (all histologies 
permitted) were randomized in a 2:1 fashion to either vande-
tanib 300 mg/day (n = 623) or erlotinib 150 mg/day (n = 617). Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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After a median duration of follow up of 14 months, this study 
failed to show any difference in PFS for patients treated with 
vandetanib (hazard ratio [HR] 0.98; 95.22% confidence interval 
[CI]: 0.87–1.10; P = 0.721). Secondary endpoints including 
overall survival, objective response rate, and time to deterio-
ration of symptoms were similar in both groups. There was a 
higher incidence of adverse events in the vandetanib group, 
including diarrhea, hypertension, and rash.
ZeAL
The ZEAL (ZACTIMA Efficacy with Alimta in Lung cancer) 
trial evaluated the addition of vandetanib to   pemetrexed.50 
The prior Phase I trial of this combination by De Boer et al37 
  demonstrated the safety and tolerability of   vandetanib when 
given with pemetrexed. Vandetanib doses of 100 mg/day were 
better tolerated than doses of 300 mg/day. This   observation 
and the concern about   theoretical antagonism with 
  chemotherapy from greater EGFR inhibition achieved with 
the 300 mg dose led De Boer and colleagues to choose the 
100 mg dose in the ZEAL study. Patients were randomized 
to vandetanib 100 mg/day plus pemetrexed 500 mg/m2 
every three weeks (n = 256) versus placebo plus pemetrexed 
(n = 278), with the primary endpoint of PFS. Secondary end-
points included overall survival, objective response rate, time 
to deterioration of symptoms, and safety. Patients received 
up to six cycles of chemotherapy. All patients had advanced 
NSCLC   previously treated with first-line therapy and all 
histologies were included. After a median follow up duration 
of nine months, this study showed a trend for improved PFS 
(HR, 0.86; 97.58% CI: 0.69–1.06, P = 0.108) and OS (HR, 
0.86; 97.54% CI: 0.65–1.13; P = 0.219); however, these 
results were not statistically significant. As demonstrated 
in other studies, the adverse events with vandetanib were 
most commonly rash (Grade 3+: 38% in vandetanib arm vs 
26% in placebo arm), diarrhea (26% vs 18%), and hyper-
tension (12% vs 3%). Interestingly, typical side effects of 
pemetrexed, such as anemia, fatigue, nausea, vomiting, 
were reduced in the arm receiving vandetanib.
Table 1 Randomized NSCLC clinical trials evaluating vandetanib
Study 
# Pts # prior chemo
Design RR (%) PFS* OS 
(m)
Randomized Phase II Trials
Kiura 200838 
53/1–2
All arms 
1. v 100 mg 
2. v 200 mg 
3. v 300 mg
13 
17.6 
5.6 
16.7
TTP 
8.3 weeks 
12.3 weeks 
12.3 weeks
–
Natale 200939 
168/1–2
1. v 300 mg 
2.   Gefitinib 250 mg daily; 
crossover allowed
8 
1
8.1 weeks 
11.3 weeks 
HR .69, P = 0.013;
6.1 
7.4 
NS
Heymach 200740 
127/1
1. Docetaxel + v 100 mg 
2. Docetaxel + v 300 mg 
3. Docetaxel
26 
18 
12
18.7 weeks^ 
17 weeks 
12 weeks^ 
^HR 0.64, P = 0.037
13.1 
7.9 
13.4
Heymach 200841 
181/chemonaive
1. Carboplatin/Paclitaxel + v 300 mg 
2. Carboplatin/Paclitaxel 
3. v 300 mg
32 
25
24 weeks (1). 
23 weeks (2) 
HR 0.76; P = 0.098 
[v alone arm closed]
10.2 
12.6 
NS
Phase III Trials
Natale 200949 
ZeST 
1240/1–2
1. v 300 mg 
2. erlotinib 
12 
12
11.3 weeks 
8.9 weeks 
HR 0.98; P = 0.721
6.9 
7.8 
NS
De Boer 200950 
ZeAL 
534/1
1. Pemetrexed + v 100 mg 
2. Pemetrexed
19 
8
17.6 weeks 
11.9 weeks 
HR 0.86; P = 0.108
10.5 
9.2 
NS
Herbst 200951 
ZODiAC 
1391/1
1. Docetaxel + v 100 mg 
2. Docetaxel
17 
10
4 months 
3.2 months 
HR 0.79; P , 0.001 
10.6 
10 
NS
Note: *PFS primary endpoint of all trials except Kiura et al study38 where RR was primary endpoint.
Abbreviations: RR, response rate; PFS, progression-free survival; OS, overall survival; m, months; TTP, time to progression; v, vandetanib (given once daily in all studies); 
NS, not statistically significant.Biologics: Targets & Therapy 2010:4 submit your manuscript | www.dovepress.com
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ZODiAC
The Phase III ZODIAC (ZACTIMA in cOmbination with 
Docetaxel In non-smAll cell lung Cancer) trial randomized 
over one thousand patients with advanced NSCLC who had 
received first line chemotherapy to two groups: vandetanib 100 
mg/day plus docetaxel 75 mg/m2 every three weeks (n = 694) 
or to placebo plus docetaxel (n = 697).51 Patients were given  up 
to 6 cycles of chemotherapy. This study had a median duration 
of follow up of 12.8 months. This study met its primary end-
point by demonstrating a   statistically significant improvement 
in PFS for the arm treated with vandetanib plus docetaxel (HR, 
0.79; 97.58% CI: 0.70–0.90; P , 0.001). Median   PFS was 8.9 
months in those   receiving vandetanib and 4 months in those 
in the chemotherapy only arm. Difference in overall survival; 
however, was not statistically significant in those receiving 
vandetanib (HR, 0.91; 97.52% CI: 0.78–1.07; P = 0.196). 
Not surprisingly, the adverse event profile was similar to that 
previously observed with vandetanib in NSCLC. Patients in 
the vandetanib arm experienced more diarrhea, rash, and neu-
tropenia. The   incidence of protocol-defined QTc prolongation 
was ,2% in patients receiving vandetanib.
Conclusions
The future of vandetanib in NSCLC is uncertain. In late   October 
2009, Astra Zeneca announced that it was   withdrawing regula-
tory submissions for use of vandetanib 100 mg in combination 
with docetaxel in patients with advanced NSCLC after initial 
application to the US FDA and the European Medicines Agency 
in June 2009. This was based on only modest PFS with no overall 
survival advantage with the addition of vandetanib to docetaxel 
Table 2 Ongoing/pending trials of vandetanib in NSCLC
Sponsor/trial Phase Target 
N
Eligibility Treatment Primary 
endpoint
AstraZeneca52 
ZePHYR 
NCT00404924
iii 930 –   Prior treatment with an  
eGFR TKi and up to 2  
chemo regimens
1. BSC + v 300 
2. BSC
OS
AstraZeneca53 
NCT00753714
Rii 122 – No prior chemo 
– $70 years of age
1. gemcitabine +v 100 
2. gemcitabine
PFS
PreCOG, LLC.54 
NCT00687297
Rii 160 –   No prior therapy  
for advanced NSCLC
1.   Docetaxel/carboplatin/ v 100 + 
maintenance v 300
2.   Docetaxel/carboplatin/v 100
PFS
AstraZeneca55 
NCT00777179
Rii 126 –   No POD after 4 cycles  
of gemcitabine/cisplatin  
for advanced NSCLC
1. Maintenance v 300 
2. Placebo
PFS
MD Anderson56 
NCT00745732
i/ii 48 –   inoperable/unresectable  
NSCLC, not candidate  
for chemo
escalating doses of v  
starting at 100 mg +  
thoracic irradiation
MTD
AstraZeneca57 
NCT00807170
i 18 –   Untreated brain metastases v 100/200/300 + wBRT MTD
MD Anderson58 
BATTLe 
NCT00410189
ii 72 –   At least one prior chemo  
for advanced NSCLC
v 300 
(biomarker directed)
PFS
MD Anderson59 
NCT00402896
ii 25 –   Symptomatic recurrent  
pleural effusion
v 300 Time until removal  
of pleurex catheter
Simmons Cancer 
Center60 
NCT00975260 
*Not yet open
R i/ii 72 Stage iiiA/B NSCLC 1.   Definitive CRT with  
carboplatin/paclitaxel + v  
followed by maintenance v
2.   Definitive CRT with  
carboplatin/paclitaxel
OS
Karmanos Cancer 
institute61 
NCT00459121
ii 15 Clinical Stage iB, ii,  
and T3N1 NSCLC
Neoadjuvant carboplatin/ 
paclitaxel + v
Complete resection 
(R0) 
*  trial completed, 
awaiting results
AstraZeneca62 
NCT00496275
i 17 Chemonaive advanced  
disease
Cisplatin/gemcitabine/v 
Cisplatin/vinorelbine/v
Safety 
*  trial completed, 
awaiting results
Abbreviations: N, number of patients; eGFR, epidermal growth factor receptor; TKi, tyrosine kinase inhibitor; BSC, best supportive care; v, vandetanib given once 
daily; R, randomized; POD, progression of disease; PFS, progression-free survival; MTD, maximum tolerated dose; wBRT, whole brain irradiation; CRT, chemoradiation;   
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in the ZODIAC trial. With negative results of the ZEAL and 
ZEST trial presented at the annual ASCO conference last year, 
further evaluation of vandetanib as monotherapy or with pem-
etrexed in unselected patients with NSCLC is unlikely. There 
are still several ongoing clinical trials evaluating vandetanib in 
various settings (see Table 2), and the results of these will help 
determine if an indication will be reached in NSCLC. Of particu-
lar importance will be the identification of clinical and molecular 
predictors of benefit from vandetanib, and correlative biomarkers 
from randomized trials are awaited. Without such predictors, 
further development of Zactima in NSCLC is unlikely.
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